← Back to Search

Alpha-radiation Imaging for Neuroendocrine Tumors

Q: Is there availability for participants in this clinical exploration?

<p>Based on the information available, this clinical trial is no longer accepting participants. It was initially posted to clinicaltrials.gov on August 22nd 2022 and last updated September 15th 2022; however, 2492 other trials are actively recruiting patients at present.</p>

Phase < 1

Waitlist Available

Research Sponsored by Yusuf Menda

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adequate performance status (ECOG of 0 or 1; or KPS of ≥70)

Aged ≥ 18 years at the time of study drug administration

Timeline

Screening 3 weeks

Treatment Varies

Follow Up study days 1 through 5

Awards & highlights

Study Summary

This trial is to see if a new imaging technique can detect neuroendocrine tumors, which will help in treating them with alpha radiation therapy.

Who is the study for?

Adults over 18 with well-differentiated neuroendocrine tumors, confirmed by pathology, that are positive for somatostatin receptors and measurable on imaging. Participants must be able to consent, follow study procedures, have a good performance status, and not have severe illnesses or conditions affecting study compliance.Check my eligibility

What is being tested?

[203Pb]VMT-α-NET is being tested to see if it can identify neuroendocrine tumors using SPECT/CT imaging. This trial is the preliminary step before testing alpha radiation therapy for these types of tumors.See study design

What are the potential side effects?

As this is a first-in-human trial for [203Pb]VMT-α-NET, specific side effects are unknown but may include typical reactions to radiopharmaceutical agents such as nausea or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can take care of myself and perform daily activities.

Select...

I am 18 years old or older.

Select...

My tumor is a Grade 1 or 2 neuroendocrine tumor, originating from the midgut or foregut.

Select...

I have a tumor that is at least 2 cm big, confirmed by CT or MRI.

Select...

I do not have any severe illnesses that would stop me from following the study's requirements.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ study days 1 through 5

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~study days 1 through 5

This trial's timeline: 3 weeks for screening, Varies for treatment, and study days 1 through 5 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Ability of [203Pb]VMT-α-NET to identify neuroendocrine tumor lesions

Secondary outcome measures

Measure radiation dose from [203Pb]VMT-α-NET dosimetrically

Single-time point survey

Trial Design

1Treatment groups

Experimental Treatment

Group I: [203Pb]VMT-α-NET SPECT/CTExperimental Treatment2 Interventions

injection of [203Pb]VMT-α-NET with serialized imaging and dosimetry measurements

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

SPECT/CT

2014

N/A

~50

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Viewpoint Molecular TargetingIndustry Sponsor

3 Previous Clinical Trials

111 Total Patients Enrolled

1 Trials studying Neuroendocrine Tumors

52 Patients Enrolled for Neuroendocrine Tumors

Yusuf MendaLead Sponsor

2 Previous Clinical Trials

50 Total Patients Enrolled

2 Trials studying Neuroendocrine Tumors

50 Patients Enrolled for Neuroendocrine Tumors

Holden Comprehensive Cancer CenterOTHER

26 Previous Clinical Trials

757 Total Patients Enrolled

5 Trials studying Neuroendocrine Tumors

97 Patients Enrolled for Neuroendocrine Tumors

Media Library

[203Pb]VMT-α-NET Clinical Trial Eligibility Overview. Trial Name: NCT05111509 — Phase < 1

Neuroendocrine Tumors Research Study Groups: [203Pb]VMT-α-NET SPECT/CT

Neuroendocrine Tumors Clinical Trial 2023: [203Pb]VMT-α-NET Highlights & Side Effects. Trial Name: NCT05111509 — Phase < 1

[203Pb]VMT-α-NET 2023 Treatment Timeline for Medical Study. Trial Name: NCT05111509 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there availability for participants in this clinical exploration?

"Based on the information available, this clinical trial is no longer accepting participants. It was initially posted to clinicaltrials.gov on August 22nd 2022 and last updated September 15th 2022; however, 2492 other trials are actively recruiting patients at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Yusuf Menda 2022. "A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05111509.